Why are higher doses of guideline‑directed medical therapy (GDMT) better in heart failure with reduced ejection fraction (HFrEF)?

Higher Doses of GDMT Significantly Reduce Mortality and Hospitalization in HFrEF

Higher doses of guideline-directed medical therapy (GDMT) are better in HFrEF because they provide a dose-dependent reduction in mortality and heart failure hospitalizations, with medium-to-optimal dosing reducing all-cause mortality by 23-27% compared to low-dose therapy. 1, 2

The Dose-Response Relationship

The evidence demonstrates a clear dose-dependent benefit:

• Medium/optimal GDMT doses reduce all-cause mortality by 23% (adjusted HR 0.77) and cardiovascular mortality by 24% (adjusted HR 0.76) at 24 months compared to low-dose therapy 1
• Each additional medication optimized to ≥50% target dose reduces mortality risk by 26% (HR 0.74 per medication) and improves 30-day hospitalization-free survival by 27% (HR 0.73) 2
• Patients on 2-4 optimally dosed GDMT medications are 3.48 times more likely to respond to cardiac resynchronization therapy compared to those on zero optimally dosed therapies 3

Why Target Doses Matter: The Mechanistic Framework

The 2022 AHA/ACC/HFSA guidelines explicitly recommend that "medication doses should be increased to target as tolerated" after initiating the four foundational drug classes (ARNI/ACEi/ARB, beta-blockers, MRAs, and SGLT2 inhibitors) 4. This recommendation is based on the fact that:

1. Clinical trials establishing efficacy used specific target doses - the mortality and morbidity benefits demonstrated in landmark trials were achieved at these target doses
2. Quadruple medical therapy at target doses reduces death risk by 73% over 2 years compared to no treatment 5
3. A 55-year-old patient transitioning from dual therapy to quadruple therapy gains an estimated 6 years of life expectancy 5

Real-World Evidence Supporting Aggressive Uptitration

Multiple contemporary studies confirm these benefits translate to clinical practice:

• Mortality benefits appear as early as 3 months with higher dosing, though statistical significance emerges more clearly at 12 and 24 months 1
• Initiation and uptitration of beta-blockers and RAS inhibitors during hospitalization for acute HFrEF improves both 30-day hospitalization-free survival (HR 0.73 and 0.77 respectively) and 1-year survival (HR 0.62 for both) 2
• Greater increases in GDMT score over time are independently associated with improved clinical outcomes, supporting the clinical relevance of longitudinal optimization 6

The Critical Implementation Gap

Despite this overwhelming evidence, real-world data reveals alarming underutilization:

• Only 25.3% of patients achieve ≥50% target dose of beta-blockers, 15.6% for RAS inhibitors, and 13.7% for MRAs at discharge 2
• In patients with severe HFrEF and advanced heart failure markers, only 41% reach ≥50% target dose of beta-blockers and just 22% for ACEi/ARB/ARNI 7
• Up to 50% of patients not receiving target doses have no documented medical reason for underdosing, suggesting clinical inertia 7

Common Pitfalls and How to Avoid Them

Pitfall #1: Sequential titration causing delays

• The 2022 guidelines explicitly state medications "may be started simultaneously at initial (low) doses" without need to achieve target dosing before initiating the next medication 4
• This approach accelerates time to optimal therapy

Pitfall #2: Stopping at "any dose" rather than target dose

• The data clearly shows that reaching ≥50% of target dose is the threshold where significant mortality benefit emerges 1, 2
• Simply prescribing these medications at low doses provides substantially less benefit

Pitfall #3: Accepting side effects as absolute contraindications

• While hypotension, bradycardia, kidney dysfunction, and hyperkalemia are common barriers 7, many patients can tolerate higher doses with careful monitoring and dose adjustments
• Nurse-directed GDMT titration programs successfully increase medication tolerance while improving ejection fraction and reducing rehospitalizations 8

The Evidence Hierarchy

The guideline recommendations 4 receive Class 1, Level A evidence for ARNI, ACEi, and ARB use with explicit instruction to uptitrate to target doses. This is reinforced by the 2023 JACC Focus Seminar 5 emphasizing rapid sequence initiation and uptitration. The most recent real-world data from 2026 1 provides the strongest contemporary evidence, showing benefits in routine clinical practice that mirror the STRONG-HF trial results.

The bottom line: Every effort should be made to reach target doses of all four foundational GDMT classes, as the mortality and morbidity benefits are dose-dependent and clinically meaningful.